The start of PhaseOut DMD in the US is in line with expectations, following regulatory clearance in April 2016. Patient enrolment is ongoing in the UK following the recruitment of the first patient in June 2016. Data from the trial will be released periodically with the first muscle biopsy data expected Q2/Q3 2017. We are currently forecasting $2.6bn of ezutromid peak sales, supported by the broad utility of the programme across all patients with DMD and in combination with other agents. We rema ....
16 Nov 2016
N+1 Singer - Summit Therapeutics - PhaseOut DMD trial underway in the US
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Summit Therapeutics - PhaseOut DMD trial underway in the US
The start of PhaseOut DMD in the US is in line with expectations, following regulatory clearance in April 2016. Patient enrolment is ongoing in the UK following the recruitment of the first patient in June 2016. Data from the trial will be released periodically with the first muscle biopsy data expected Q2/Q3 2017. We are currently forecasting $2.6bn of ezutromid peak sales, supported by the broad utility of the programme across all patients with DMD and in combination with other agents. We rema ....